RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST - Get Free Report) insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $50.09, for a total value of $155,279.00. Following the transaction, the insider now owns 42,246 shares of the company's stock, valued at approximately $2,116,102.14. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total value of $155,589.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Trading Down 1.3 %

Shares of NASDAQ:RXST traded down $0.65 on Tuesday, hitting $49.61. The company had a trading volume of 211,049 shares, compared to its average volume of 476,147. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -39.37 and a beta of 1.20. The stock has a 50 day moving average price of $52.03 and a 200 day moving average price of $53.87. RxSight, Inc. has a 1-year low of $20.66 and a 1-year high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.06. The business had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. RxSight's quarterly revenue was up 67.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) EPS. Sell-side analysts anticipate that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RXST has been the subject of a number of analyst reports. Wells Fargo & Company decreased their price target on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Oppenheimer dropped their price target on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. BTIG Research lifted their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a "buy" rating in a research report on Monday, July 15th. Finally, Stifel Nicolaus lowered their price objective on shares of RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $60.14.

Hedge Funds Weigh In On RxSight

A number of large investors have recently made changes to their positions in RXST. Marshall Wace LLP acquired a new position in RxSight in the 2nd quarter valued at $19,512,000. Driehaus Capital Management LLC boosted its position in shares of RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company's stock valued at $42,490,000 after acquiring an additional 302,367 shares during the period. Baillie Gifford & Co. grew its stake in shares of RxSight by 438.8% in the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company's stock valued at $21,554,000 after acquiring an additional 291,733 shares in the last quarter. William Blair Investment Management LLC bought a new position in RxSight during the second quarter worth about $14,942,000. Finally, M&G Plc acquired a new stake in RxSight in the 1st quarter worth about $7,354,000. Institutional investors own 78.78% of the company's stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.